Hyderabad: Seven children from different parts of India suffering from Allan-Herndon-Dudley Syndrome (AHDS), an extremely rare genetic disorder that causes severe muscle weakness, are set to receive free medication following an initiative led by Hyderabad-based paediatrician Dr Shivaranjani Santosh.

Dr Santosh has arranged the medicines in collaboration with the Netherlands-based Pharmaceutical Accountability Foundation (PAF) and K M Gopakumar, a representative of the civil society collective Access to Medicines India.

The initiative is expected to provide significant relief to the families, who otherwise face enormous financial challenges in accessing treatment. The branded medicines required to manage the condition cost between Rs 4.68 crore and Rs 9 crore per child annually, making lifelong treatment virtually unaffordable for most families.

The medicines, available in tablet and capsule forms, need to be taken throughout the patient’s lifetime.

Generic medicine brings treatment cost down to Rs 2.5 lakh

The high cost of branded medication has been a major obstacle for families of children diagnosed with AHDS. The annual treatment expenditure running into several crores has made access to medicines extremely difficult, with several affected children reportedly losing their lives amid challenges in obtaining treatment.

A major breakthrough came when Transvaal Pharmacy in the Netherlands developed a generic version of the medicine with support from donors.

The availability of the generic formulation has brought down the annual treatment cost to approximately Rs 2.5 lakh per child, compared with the earlier cost of several crores.

This reduction has opened up the possibility of sustained treatment for families who were previously unable to afford the branded medication.

The initiative involving Dr Santosh, PAF and Access to Medicines India has helped mobilise resources to procure the medicines for seven children.

Rs 15.09 lakh raised for seven children

A total of Rs 15.09 lakh was required to arrange the medicines for all seven children.

Dr Santosh raised Rs 6.09 lakh through donors in India, while a Netherlands-based foundation contributed the remaining Rs 9 lakh.

The medicines will be formally handed over to the parents of the affected children on November 30.

The arrangement is expected to ease the immediate financial burden on the families and help the children access medication that would otherwise remain beyond their reach.

The initiative also highlights the role of international collaboration, donor support and civil society organisations in addressing the challenges associated with rare diseases and expensive treatments.

AHDS poses serious challenges for affected children

Allan-Herndon-Dudley Syndrome is a rare genetic disorder associated with severe muscle weakness. Children affected by the condition require specialised medical attention and access to appropriate medication.

The lifelong nature of treatment makes the cost of medicines a particularly serious concern for families. When the annual expense runs into several crores, even families with access to specialist medical care may struggle to continue treatment.

The development of a significantly cheaper generic formulation could therefore make a substantial difference to patients, provided the medicine remains accessible and its supply is sustained.

Dr Santosh plans to seek domestic manufacturing

While welcoming the arrangement, Dr Shivaranjani Santosh said importing medicines from abroad could not be considered a permanent solution.

She plans to approach the Central government to explore the possibility of manufacturing the medicine in India. Domestic production, she believes, could help ensure more reliable access and reduce dependence on imports.

She also said a special survey was being conducted in collaboration with medical experts to identify more children across the country suffering from AHDS.

Identifying additional patients would help establish a clearer picture of the number of affected children and their treatment requirements.

The initiative to provide medication to seven children is an important step towards addressing the affordability challenge associated with rare genetic disorders. The proposed efforts to identify more patients and explore domestic manufacturing could help extend access to treatment to other affected families across the country.